Table III.
Association of DLGAP5 expression levels with clinical characteristics of patients with breast cancer.
| DLGAP5 expression levels | ||||
|---|---|---|---|---|
| Clinical characteristics | Strong, n | Weak, n | χ2 | P-value |
| Age, years | 0.639 | 0.420 | ||
| ≤50 | 34 | 58 | ||
| >50 | 21 | 47 | ||
| T stage | 0.420 | 0.520 | ||
| 1-2 | 41 | 83 | ||
| 3-4 | 14 | 22 | ||
| Lymph node | 5.806 | 0.016a | ||
| − | 27 | 72 | ||
| + | 28 | 33 | ||
| Clinical stage | 4.002 | 0.045a | ||
| I–IIB | 38 | 87 | ||
| IIIA-IIIB | 17 | 18 | ||
| ER status | 0.347 | 0.556 | ||
| + | 43 | 84 | ||
| − | 10 | 15 | ||
| PR status | 0.022 | 0.882 | ||
| + | 32 | 61 | ||
| − | 21 | 38 | ||
| Her-2 status | 3.061 | 0.080 | ||
| 3+ | 8 | 6 | ||
| 0-1 | 45 | 89 | ||
a
P<0.05. DLGAP5, discs large-associated protein 5; T, tumor; ER, estrogen receptor; PR, progesterone receptor; Her-2, human epidermal growth factor receptor-2.